{"links":{"html":"https://www.erudio.com/reports/excaliber-rrmm-nct04975997","json":"https://www.erudio.com/reports/excaliber-rrmm-nct04975997.json","markdown":"https://www.erudio.com/reports/excaliber-rrmm-nct04975997.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"excaliber-rrmm-04975997"}},"request":"https://www.erudio.com/contact?report=excaliber-rrmm-04975997"},"offer":{"cited_commentary_sources":52,"verified_hcp_statements":664,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":22,"optional":true,"price_per_verified_person_usd":15,"price_usd":330,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"excaliber-rrmm-nct04975997"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=excaliber-rrmm-04975997","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/excaliber-rrmm-nct04975997","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-18T22:40:52.018088Z","notify_subscribers":false,"status":"new","summary":{"reason":"Initial accepted edition has no weekly change log.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":15,"no_commentary_found":0},"aspects":[{"claim_count":24,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":19,"title":"Primary endpoint: Progression-free Survival (PFS)"},{"claim_count":29,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":20,"title":"Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time"},{"claim_count":15,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":37,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":15,"title":"Population and setting"},{"claim_count":30,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":48,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":16,"title":"Safety and tolerability"},{"claim_count":25,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":11,"title":"Design and conduct"},{"claim_count":38,"coverage":"discussed","id":"A1","source_count":13,"title":"Position among early-relapse treatment alternatives"},{"claim_count":62,"coverage":"discussed","id":"A2","source_count":12,"title":"Shared decisions, community delivery and referral"},{"claim_count":39,"coverage":"discussed","id":"A3","source_count":13,"title":"CELMoD identity, mechanism and prior IMiD refractoriness"},{"claim_count":71,"coverage":"discussed","id":"A4","source_count":27,"title":"MRD-based approval, evidence release and early access"},{"claim_count":47,"coverage":"discussed","id":"A5","source_count":8,"title":"MRD ascertainment, routine monitoring and treatment decisions"},{"claim_count":69,"coverage":"discussed","id":"A6","source_count":12,"title":"Combinations, bridging and sequencing with immune therapies"},{"claim_count":9,"coverage":"discussed","id":"A7","source_count":3,"title":"Representation, applicability and recruitment equity"},{"claim_count":55,"coverage":"discussed","id":"A8","source_count":12,"title":"Supportive care, prescribing constraints and alternative-treatment management"}],"counts":{"cited_sources":52,"claims_by_expression_type":{"comparison":103,"experience":39,"interpretation":119,"opinion":83,"question":71,"restatement":60,"uncertainty":65,"unspecified":124},"claims_by_kind":{"attributed_opinion":38,"interpretation":39,"limitation":16,"source_observation":571},"clinician_statements":248,"evidence_units":314,"findings":12,"people_cited":39,"people_identity_verified":22,"people_total":40,"screened_sources":61,"verified_claims":664},"depth":"rich","findings_index":[{"id":"F1","structure":{"claims":39,"claims_by_group":{"comparisons":2,"experience":0,"questions":11,"restated":17,"views":9},"has_counterview":true,"limitations":3,"links":{"context":6,"support":42},"ma_question":true,"named_voices":14,"passages":29,"sources":15,"sources_by_kind":{"commentary":7,"media":8}},"title":"Modern maintenance failure exposes unresolved treatment-fit questions"},{"id":"F2","structure":{"claims":52,"claims_by_group":{"comparisons":19,"experience":3,"questions":7,"restated":12,"views":11},"has_counterview":true,"limitations":3,"links":{"context":17,"support":63},"ma_question":true,"named_voices":11,"passages":43,"sources":17,"sources_by_kind":{"commentary":8,"media":9}},"title":"Favorable tolerability assessments coexist with consequential hematologic, infectious and vascular concerns"},{"id":"F3","structure":{"claims":32,"claims_by_group":{"comparisons":3,"experience":5,"questions":5,"restated":8,"views":11},"has_counterview":true,"limitations":3,"links":{"context":6,"support":33},"ma_question":true,"named_voices":11,"passages":24,"sources":12,"sources_by_kind":{"commentary":7,"media":5}},"title":"Manageability depends on individualized supportive care, dose holds and medication review"},{"id":"F4","structure":{"claims":40,"claims_by_group":{"comparisons":14,"experience":1,"questions":7,"restated":6,"views":12},"has_counterview":true,"limitations":2,"links":{"context":3,"support":40},"ma_question":true,"named_voices":10,"passages":28,"sources":13,"sources_by_kind":{"commentary":7,"media":6}},"title":"BCMA-first preferences coexist with conditional replacement of conventional triplets"},{"id":"F5","structure":{"claims":46,"claims_by_group":{"comparisons":13,"experience":1,"questions":12,"restated":13,"views":7},"has_counterview":true,"limitations":4,"links":{"context":7,"support":48},"ma_question":true,"named_voices":20,"passages":37,"sources":30,"sources_by_kind":{"commentary":18,"media":12}},"title":"Response-depth enthusiasm and reported PFS do not settle comparative treatment position"},{"id":"F6","structure":{"claims":75,"claims_by_group":{"comparisons":1,"experience":3,"questions":23,"restated":28,"views":20},"has_counterview":true,"limitations":3,"links":{"context":10,"support":84},"ma_question":true,"named_voices":22,"passages":64,"sources":27,"sources_by_kind":{"commentary":14,"media":13}},"title":"MRD-based early access divides assessments of evidentiary readiness"},{"id":"F7","structure":{"claims":47,"claims_by_group":{"comparisons":8,"experience":1,"questions":7,"restated":10,"views":21},"has_counterview":true,"limitations":3,"links":{"context":1,"support":68},"ma_question":true,"named_voices":9,"passages":35,"sources":8,"sources_by_kind":{"commentary":4,"media":4}},"title":"MRD’s meaning depends on denominator, timing and the intended clinical action"},{"id":"F8","structure":{"claims":41,"claims_by_group":{"comparisons":8,"experience":4,"questions":3,"restated":20,"views":6},"has_counterview":true,"limitations":3,"links":{"context":8,"support":50},"ma_question":true,"named_voices":11,"passages":24,"sources":13,"sources_by_kind":{"commentary":4,"media":9}},"title":"Dose optimization earns praise while comparator asymmetry draws scrutiny"},{"id":"F9","structure":{"claims":39,"claims_by_group":{"comparisons":10,"experience":0,"questions":7,"restated":10,"views":12},"has_counterview":true,"limitations":3,"links":{"context":15,"support":46},"ma_question":true,"named_voices":8,"passages":31,"sources":13,"sources_by_kind":{"commentary":3,"media":10}},"title":"CELMoD differentiation is argued biologically and clinically, but class taxonomy is contested"},{"id":"F10","structure":{"claims":112,"claims_by_group":{"comparisons":12,"experience":12,"questions":25,"restated":16,"views":47},"has_counterview":true,"limitations":4,"links":{"context":25,"support":121},"ma_question":true,"named_voices":15,"passages":74,"sources":14,"sources_by_kind":{"commentary":4,"media":10}},"title":"Patient choice and community feasibility depend on local capability and alternative-specific burdens"},{"id":"F11","structure":{"claims":69,"claims_by_group":{"comparisons":6,"experience":0,"questions":16,"restated":15,"views":32},"has_counterview":true,"limitations":3,"links":{"context":14,"support":71},"ma_question":true,"named_voices":10,"passages":47,"sources":12,"sources_by_kind":{"commentary":1,"media":11}},"title":"CELMoDs are envisioned as partners and sequencing tools, with investigational limits"},{"id":"F12","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":4,"views":4},"has_counterview":false,"limitations":2,"links":{"context":4,"support":9},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"media":3}},"title":"Underrepresentation prompts applicability and recruitment concerns"}],"medical_affairs_question":"Which prior-treatment histories distinguish an evidence-supported IberDd discussion from extrapolation after modern maintenance failure?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Prior exposure is not the same treatment-fit question as maintenance failure"},{"id":"section-2","level":2,"title":"Less nonhematologic burden does not mean an uncomplicated safety profile"},{"id":"section-3","level":2,"title":"Manageability assumes active, individualized intervention"},{"id":"section-4","level":2,"title":"Replacing a conventional triplet is not the same as displacing CAR T or a bispecific"},{"id":"section-5","level":2,"title":"Response depth inspires confidence; comparative positioning remains open"},{"id":"section-6","level":2,"title":"Earlier access is not the same judgment as readiness to choose treatment"},{"id":"section-7","level":2,"title":"The same MRD label can describe different populations, time windows and decisions"},{"id":"section-8","level":2,"title":"Dose-selection praise does not answer the comparator question"},{"id":"section-9","level":2,"title":"A clinically distinct class—or a more potent version of the same mechanism?"},{"id":"section-10","level":2,"title":"Choice depends on what the patient wants and the setting can support"},{"id":"section-11","level":3,"title":"Alternatives bring different burdens, not interchangeable advantages"},{"id":"section-12","level":2,"title":"Partnership enthusiasm exceeds certainty about the best sequence"},{"id":"section-13","level":2,"title":"Representation affects what clinicians can learn for patients they actually see"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":9},{"id":"F6","shared_claims":14}],"id":"T1","label":"Primary endpoint: Progression-free Survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F5","shared_claims":16},{"id":"F6","shared_claims":2},{"id":"F7","shared_claims":11},{"id":"F8","shared_claims":1}],"id":"T2","label":"Primary endpoint: Minimal Residual Disease (MRD) negative Complete Response (CR) at any time"},{"findings":[{"id":"F3","shared_claims":2},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":6},{"id":"F7","shared_claims":1},{"id":"F10","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":36},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":8},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":22}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":43},{"id":"F3","shared_claims":5},{"id":"F5","shared_claims":1},{"id":"F10","shared_claims":2}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":24},{"id":"F12","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-18T22:40:52.018088Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-18T23:53:15Z","record_hash":"2c30b3af0c86e431744a93b2a045b7dcec10e9a4db253849b39450ee8c7158da","release_hash":"72f581d56a26867e363420c64eba3fe5c0b59fb5cd562ab32ae490816155c2bb","report_id":"erudio-nct04975997","run_id":"ad98cdd4-8db3-40da-8537-480ba25487dd","schema_version":"5.0","slug":"excaliber-rrmm-04975997","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"EXCALIBER-RRMM raises the question of where iberdomide with daratumumab and dexamethasone fits for patients with relapsed or refractory multiple myeloma. Clinicians discuss prior-treatment history and modern maintenance failure, comparisons with other relapse options, response durability, safety and supportive care, and patient preferences, access and referral. Other topics include dose selection and comparator design, minimal residual disease (MRD) measurement and routine testing, and evidence needed for accelerated approval and individual treatment decisions. The sources reviewed for this edition span different stages of evidence availability.","meta_description":"61 sources screened · 664 verified statements (248 from speakers with a confirmed clinical role) from 52 sources · 12 findings. Updated Oct 18, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-46f0cfca43992ee7ca68"],"id":"F6","paraphrase":"In a YouTube discussion, a speaker asked how the FDA might weigh co-primary endpoints when MRD-negativity data were mature but PFS remained immature, including scenarios with few PFS events or a possible early unfavorable PFS signal.","publication_caveats":{"reason":"Source-specific publication caveats are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-03-31","title":"MRD-based early access divides assessments of evidentiary readiness"},{"cited_claim_ids":["claim-cab2f046b9b099b87bc9"],"id":"F1","paraphrase":"In a YouTube discussion, a speaker asked whether trial participants were refractory to IMiDs and had previously received anti-CD38 therapy.","publication_caveats":{"reason":"Source-specific publication caveats are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"youtube","source_date":"2026-04-10","title":"Modern maintenance failure exposes unresolved treatment-fit questions"}]},"publication":{"approved_at":"2026-10-18T23:53:15Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":61},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","Out of scope: 4 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.","26 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits apply, so some matching discussion may be missing.","The sources reviewed for this edition are a selected set of public and educational discussions, not a representative survey. Repeated recordings, related posts and account commentary cannot be counted as independent clinicians or used to estimate consensus.","The discussions span anticipation of results, MRD-based approval accounts, subsequent PFS reporting and publication-sharing. Their information states differ; dates and sequence alone do not establish that an individual changed position.","No full trial-results publication or trial protocol text is available for this report. A post sharing the manuscript does not supply its contents. Some speakers relied on press releases or prescribing information, so their numerical summaries and interpretations cannot be independently adjudicated here.","The regulatory material is incomplete, including the absence of an exact daratumumab label. Regulatory descriptions, approval timing and label-based implementation details remain attributed statements rather than independently confirmed regulatory conclusions.","Some potentially relevant recordings could not be read, and some passages could not be fully assessed. Discussion that used unnamed references or different spellings may also be missing.","Several recording voices could not be identified. Their views remain unnamed, and account posts or relayed recommendations are not treated as direct statements by an inferred individual.","The sources do not establish Mehak Trehan’s or Preetam Jain’s clinical role. Their posts are treated as attributed commentary, without assigning a specialty or practice setting.","Some source accounts differ about prior treatment, eligibility, regimen components, comparator wording, MRD assessment and adverse-event rates. Those differences are preserved rather than reconciled into a single factual description.","Cross-trial rankings are clinicians’ comparative interpretations, not head-to-head findings. Statements about other regimens retain their own population, setting, timing and supportive-care conditions.","Future combinations, bridging strategies, immune-enhancement hypotheses and maintenance proposals are not treated as established benefits or prescribing recommendations for the EXCALIBER-RRMM regimen."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":9,"publication":0,"registry":0,"regulatory":0,"x_thread":34,"x_video":2,"youtube":7},"by_evidence_role":{"commentary":52},"count":52,"evidence_window":{"end":"2026-10-13","start":"2024-07-04"},"retrieval_snapshot":"2026-10-18T19:49:30.136079Z","timeline":[{"count":1,"week":"2024-W27"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W14"},{"count":2,"week":"2026-W15"},{"count":1,"week":"2026-W27"},{"count":8,"week":"2026-W33"},{"count":9,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":10,"week":"2026-W39"},{"count":6,"week":"2026-W40"},{"count":5,"week":"2026-W41"},{"count":5,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04975997:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04975997:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40346992","quote_policy":"no_derivatives"},{"id":"pubmed:42790445","quote_policy":"short_quote_link_out"},{"id":"openfda:11f10a47-1c42-40e4-89d8-bb000fef497c:20260909","quote_policy":"short_quote_link_out"},{"id":"openfda:b605b541-4bfd-db3e-9710-11c27f6dee6c:20260909","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3ff437","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4cad34","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:529d9e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:575778","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5c7572","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:6b56a6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:76b3e5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:9bc2b2","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:ff8188","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1893420223895625758:cbf0f911-242f-4ffc-999c-69a399d4ac9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980334765627830577:04f9cac2-02cb-4728-96d7-96825be6a01d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087996580250964156:61647d7d-606f-415d-a785-7f3f76094ccb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088026570451735033:d9e30c3f-f818-43c7-94d3-d69c348a81b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088039041111319009:b8c421b5-cc80-4e4b-8e39-9a923078e1a7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088048114624028902:fe638e02-6abe-4672-979c-e43156aaa5c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088077743066054801:fef8a4a3-c5db-4a49-b5e5-d84a2c588560","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088102332307284407:b8e56f15-07ad-4502-81e8-4863ae457c0f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088249148596199572:818eafb0-dbc0-4a55-bb90-1e1eaf7a72f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088271209427607703:1d1a07a1-6d25-4ebc-8a27-c04e96fd3214","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088457996691189977:66d9949c-cfb8-4170-b876-2deb6ef5fbb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088636500174839883:136ce83e-4bd5-48dd-8cc9-1b7744fac520","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089418897229328775:cd85a179-c6aa-429f-934a-f6a1ced63a88","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089677383007662410:e22e9766-4e5c-441f-afb0-0e05246aca78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089899953954988179:9ef55eaa-2895-4f87-89d3-12acf981790b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090460056735055951:f6e41dfd-5600-489d-a0f0-03e6d10151bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090788231092568531:7d7ee025-9a4c-4bdb-8a5a-a2770023a95e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102120445818343587:633ce029-00d6-4c16-82e5-5e8f54773f25","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102152227913629700:2589195b-cbf6-4c4c-91e6-813d84ed4cdc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103486988141924658:1d2c0a99-c6d7-4cf7-b97e-f63807b2aba6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103498749737652489:98abebde-dbc1-4057-bfa9-0960b610c780","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103498890893021564:1952d1e0-af11-4661-a596-f20c39cde4ce","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103499316132200758:1d6ac48f-289d-4c86-82f4-9a7e44aac36d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103502176727224643:b9abcaa0-e1f8-4805-a190-b5454ac7e7ec","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103507303022707071:eb32f71c-5e23-4889-bdba-a70848b2015c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103508724664914193:fd34a01c-bddf-4dbb-8866-14793fdc4129","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103511244594389489:fb6b8577-5921-4167-893b-d25290a001e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103515889408647465:8f31db10-366b-4fdf-94d0-291a2dc25ff9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104194354717884773:d73a1fed-8417-454f-8bcb-a705d939819f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104587612602409253:a0a9e050-5f99-4589-9751-915424727f50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104894600976494739:1da0d2a9-b40c-499d-bc4a-0e2ab3e3ff84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104981009192153232:aee2a638-e67f-4d01-9596-f2093a411567","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105001864500789688:8497a754-59c4-4011-af62-b22b6f10fd26","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105325809494093860:8c8e96ed-b96a-442a-9900-f35c708ae995","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105650649862156598:804369b0-bfb5-4153-a9d5-9b33d30ba252","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108164153471119496:c79241dd-51ed-4423-b292-9766291ea59b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108166918473728242:45a60564-4395-4d4a-824d-fd485dca19f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108189475339710464:23a6141f-e2b6-4985-8d7b-5a8971648772","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108742921398964674:655178ca-7492-47f1-9dc2-7e7947c41002","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109244278027526321:808dd3bc-09d1-44b7-8df6-e8c6025e2397","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109538646483198068:2ff534b5-433b-4b49-ad49-55d1cac0cc11","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109597540135882793:6c078edd-c259-4743-a9d0-247bd4e2879a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2109651035405078556:f32f79d2-0feb-42ea-b04a-638d789dc4b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2093920026097049818","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2103805856793899314","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:7rdK63tJf74","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FDvIXRpsILg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FxYVTlXCSA4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Mra_LHZSnqI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TaGetEwu3Sw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:f81aqnxlA_Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uC979HAggEM","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":9,"publication":0,"registry":0,"regulatory":0,"x_thread":43,"x_video":2,"youtube":7},"by_evidence_role":{"commentary":61},"count":61,"evidence_window":{"end":"2026-10-13","start":"2024-07-04"},"retrieval_snapshot":"2026-10-18T19:49:30.136079Z","timeline":[{"count":1,"week":"2024-W27"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2026-W11"},{"count":1,"week":"2026-W14"},{"count":2,"week":"2026-W15"},{"count":1,"week":"2026-W27"},{"count":10,"week":"2026-W33"},{"count":9,"week":"2026-W34"},{"count":2,"week":"2026-W35"},{"count":13,"week":"2026-W39"},{"count":8,"week":"2026-W40"},{"count":6,"week":"2026-W41"},{"count":5,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Decadron","Dexacen-4","Dexone","Hemady","Hexadrol","Taperdex"],"label":"dexamethasone","slug":"dexamethasone"},{"brand_names":["Darzalex"],"label":"daratumumab","slug":"daratumumab"},{"brand_names":["Velcade"],"label":"bortezomib","slug":"bortezomib"},{"reason":"Unmapped registry intervention: iberdomide","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Multiple myeloma","slug":"multiple-myeloma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"EXCALIBER-RRMM","aliases":["EXCALIBER-RRMM","Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)"],"brief_title":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Multiple Myeloma"],"enrollment":{"count":939,"type":"ACTUAL"},"interventions":[{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":["DARZALEX FASPRO"],"type":"DRUG"},{"name":"Bortezomib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Iberdomide","synonyms":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Iberdomide","synonyms":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Iberdomide","synonyms":["CC-220","BMS-986382"],"type":"DRUG"},{"name":"Dexamethasone","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Daratumumab","synonyms":["DARZALEX FASPRO"],"type":"DRUG"}],"nct_id":"NCT04975997","official_title":"A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2027-11-16","type":"ESTIMATED"},"primary_endpoints":[{"description":"To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of progression free survival (PFS).","measure":"Progression-free Survival (PFS)","timeFrame":"Up to approximately 5 years"},{"description":"To compare the efficacy of iberdomide (also known as BMS-986382), daratumumab, and dexamethasone (IberDd) to that of daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) in terms of minimal residual disease (MRD) negative complete response (CR) at any time.","measure":"Minimal Residual Disease (MRD) negative Complete Response (CR) at any time","timeFrame":"Up to approximately 5 years"}],"registry_last_updated":"2026-04-03","registry_url":"https://clinicaltrials.gov/study/NCT04975997","short_name":"EXCALIBER-RRMM","short_name_basis":"registry_acronym","sponsor":"Celgene","start_date":{"date":"2022-06-23","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CC-220-MM-002","type":"sponsor_study_id"},{"domain":"UTN Number","id":"U1111-1260-2872","type":"other"},{"id":"2020-000431-49","type":"eudract_number"}],"study_type":"INTERVENTIONAL"}}}